

# CONFERENCE PROGRAM

## THURSDAY, MAY 4

**15:00-17:00**

**Educational Session: Genomics**

Grand Ballroom I & II

**Session Chair: Lillian L. Siu**, Princess Margaret Cancer Centre, Toronto, ON, Canada

- |             |  |
|-------------|--|
| 15:00-15:20 | Molecular tumor board - Case presentation<br>Lillian L. Siu and William C. Hahn  |
| 15:20-15:55 | Clinical applications: Drug access and design of genotype-specific trials<br>Lillian L. Siu  |
| 15:55-16:30 | Opportunities for translational and discovery research: Next-Gen genomics<br>William C. Hahn, Dana-Farber Cancer Institute, Boston, MA |
| 16:30-17:00 | Panel discussion/Questions from audience<br>Lillian L. Siu and William C. Hahn   |

**17:00-17:30**

**Break**

Grand Ballroom Foyer

**17:30-18:00**

**Welcome and Opening Remarks**

Grand Ballroom I & II

Margaret Foti, American Association for Cancer Research, Philadelphia, PA

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

Carlos Gil M. Ferreira, D'or Institute for Research and Education, Rio de Janeiro, Brazil

**18:00-19:30**

**Plenary Session 1: Immune Checkpoints: Successes and What We Have Learned**

Grand Ballroom I & II

**Session Chair: João P.B. Viola**, Brazilian National Cancer Institute, Rio de Janeiro, Brazil

- |             |   |
|-------------|---|
| 18:00-18:30 | Selective pressure by activated T cells identifies de novo and adaptive resistance mechanisms in melanoma<br>Keith T. Flaherty, Massachusetts General Hospital Cancer Center, Boston, MA                |
| 18:30-19:00 | State of clinical success of immune checkpoints (new preclinical data on anti-PD-1 and anti-PDL-1)<br>Cristina B. Bonorino, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil |
| 19:00-19:30 | ER stress responses as new immune checkpoints in cancer<br>Juan R. Cubillos-Ruiz, Weill Cornell Medical College, New York, NY   |

**19:45-21:30**

**Opening Reception**

Grand Ballroom III and Foyer

# CONFERENCE PROGRAM

## FRIDAY, MAY 5

**08:30-09:15**

**Keynote Lecture 1**

Grand Ballroom I & II

**Session Chair: Carlos Gil M. Ferreira**, D'or Institute for Research and Education, Rio de Janeiro, Brazil

The different facets of cervical cancer prevention

Luisa L. Villa, Fundação Faculdade de Medicina de São Paulo, São Paulo, Brazil

**09:15-09:45**

**Break**

Grand Ballroom Foyer

**09:45-10:45**

**Plenary Session 2: Tumor Heterogeneity**

Grand Ballroom I & II

**Session Chair: Felipe C. Geyer**, Memorial Sloan Kettering Cancer Center, New York, NY

9:45-10:15

The dynamics of cancer cell heterogeneity

Guido Lenz, Federal University of Rio Grande do Sul, Porto Alegre, Brazil

10:15-10:45

Intratumor genetic heterogeneity

Felipe C. Geyer

**10:45-11:00**

**Break**

Grand Ballroom Foyer

**11:00 -12:30**

**Plenary Session 3: Hematologic Malignancies**

Grand Ballroom I & II

**Session Chair: Eliana Abdelhay**, Brazilian National Cancer Institute, Rio de Janeiro, Brazil

11:00-11:30

Epigenetic mechanisms in pathogenesis and targeted therapy for B-cell lymphomas

Ari M. Melnick, Weill Cornell Medical College, New York, NY

11:30-12:00

Clinical networking as a tool to improvement of leukemia care and research in developing countries: The experience of the International Consortium on Acute Leukemias (ICAL)

Eduardo Magalhães Rego, University of São Paulo, São Paulo, Brazil

12:00-12:30

Novel therapeutic targets in multiple myeloma

Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, MA

# CONFERENCE PROGRAM

**12:30 -15:00**

**Poster Session A/Lunch**

Grand Ballroom III and Foyer

**15:15-16:45**

**Plenary Session 4: Precision Medicine/Targeted and Combination Therapies/Drug Resistance**

Grand Ballroom I & II

**Session Chair: Oscar G. Arrieta**, Instituto Nacional de Cancerología, Mexico City, Mexico

15:15-15:45      A systems approach to rational combination therapy with PARP inhibitors  
Gordon B. Mills, The University of Texas MD Anderson Cancer Center, Houston, TX

15:45-16:15      Overcoming drug resistance and tumor heterogeneity in gastrointestinal cancers  
Ryan B. Corcoran, Massachusetts General Hospital Cancer Center, Boston, MA

16:15-16:45      Evolution and clinical impact of co-occurring genetic alterations in lung cancer  
Trever G. Bivona, University of California, San Francisco, CA

**16:45-17:00**

**Break**

Grand Ballroom Foyer

**17:00-18:30**

**Plenary Session 5: Liquid Biopsies/Organoids/PDX**

Grand Ballroom I & II

**Session Chair: Andrés F. Cardona**, Fundación Santa Fe de Bogotá, Bogotá, Colombia

17:00-17:30      Circulating tumor DNA as a “liquid biopsy” for precision medicine: Basic concepts  
Anamaria A. Camargo, Ludwig Institute for Research on Cancer, São Paulo, Brazil

17:30-18:00      Cancer evolution as a therapeutic target  
Alberto Bardelli, University of Turin School of Medicine, Candiolo, Italy

18:00-18:30      Patient-derived xenografts and organoids to predict therapeutic response  
for breast cancer patients  
Alana L. Welm, University of Utah Huntsman Cancer Institute, Salt Lake City, UT

**18:30-**

**Evening Off/Dinner on Own**

# CONFERENCE PROGRAM

## SATURDAY, MAY 6

**08:30-09:15**

**Keynote Lecture 2**

Grand Ballroom I & II

**Session Chair: Carlos L. Arteaga**, Vanderbilt-Ingram Cancer Center, Nashville, TN

Defining a cancer dependencies map

William C. Hahn, Dana-Farber Cancer Institute, Boston, MA

**09:15-09:45**

**Break**

Grand Ballroom Foyer

**09:45-11:15**

**Plenary Session 6: DNA Repair and PARP Inhibitors**

Grand Ballroom I & II

**Session Chair: Dyeison Antonow**, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

09:45-10:15

Targeting DNA repair in cancer therapy

Alan D. D'Andrea, Dana-Farber Cancer Institute, Boston, MA

10:15-10:45

PARP trapping and Schlafen 11 to kill cancer cells

Yves G. Pommier, National Cancer Institute-CCR, Bethesda, MD

10:45-11:15

Methods for defining DNA repair defects in human cancer

Simon N. Powell, Memorial Sloan Kettering Cancer Center, New York, NY

**11:15-11:30**

**Break**

Grand Ballroom Foyer

**11:30-13:00 pm**

**Plenary Session 7: Hormone-Dependent Cancers and Steroid Receptors**

Grand Ballroom I & II

**Session Chair: Carlos H. Barrios**, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil

11:30-12:00

Lessons for ER+ breast cancer from neoadjuvant endocrine therapy trials

Matthew J. Ellis, Baylor College of Medicine, Houston, TX

12:00-12:30

Targeting DNA repair dysfunction in prostate cancer

Karen E. Knudsen, Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, PA

12:30-13:00

Targeting DNA repair deficiencies in breast cancer

Samuel Aparicio, BC Cancer Research Centre, Vancouver, BC, Canada

**13:00-15:00**

**Poster Session B/Lunch**

Grand Ballroom III and Foyer

# CONFERENCE PROGRAM

## **15:15-16:45 Plenary Session 8: Oncogenes and Tumor Suppressors**

Grand Ballroom I & II

**Session Chair: Roger Chammas**, University of São Paulo, São Paulo, Brazil

- 15:15-15:45 Strategies to prevent and treat resistance to EGFR inhibitors in lung cancer  
Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, MA
- 15:45-16:15 Tumor suppressor and tumor maintenance genes  
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, NY
- 16:15-16:45 Long noncoding RNA-mediated RNA editing as a new mechanism of tumor suppressor gene inactivation  
Emmanuel Dias-Neto, A.C. Camargo Cancer Center, São Paulo, Brazil

## **16:45-17:00 Break**

Grand Ballroom Foyer

## **17:00-18:30 Plenary Session 9: Epigenetics**

Grand Ballroom I & II

**Session Chair: Paulo M. Hoff**, Centro de Oncologia, São Paulo, Brazil

- 17:00-17:30 Title to be announced  
Daniel De Carvalho, Princess Margaret Cancer Centre, Toronto, ON, Canada
- 17:30-18:00 The promise among the setbacks for epigenetic therapy in solid tumors  
Nilofer S. Azad, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
- 18:00-18:30 Defining cancer specific epigenomic signature associated with glioma progression  
Houtan Noushmehr, University of São Paulo, Ribeirao Preto, Brazil

## **18:30-18:45 Closing Remarks**

Grand Ballroom I & II

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN

Carlos Gil M. Ferreira, D'or Institute for Research and Education, Rio de Janeiro, Brazil